Unicycive Therapeutics

Unicycive makes new medicines for people with kidney diseases. These treatments help patients manage dangerous levels of minerals. The company focuses on specific needs in the United States.

Helping Kidneys Recover

• Renazorb: A potential treatment for patients with chronic kidney disease; it targets hyperphosphatemia, which is a condition involving high phosphorus levels in the blood.
• UNI 494: A drug candidate designed to treat acute kidney injury, which is sudden and short-term damage to the kidneys.

Strategic Moves and Alliances

• Amended a manufacturing agreement with Shilpa Medicare Ltd in June 2024 to increase production capacity for tablets.
• Partnered with Lee's Pharmaceutical (HK) Limited in July 2022 to develop and sell Renazorb in China and Hong Kong.
• Granted drug development and commercialization rights for the South Korean market to Lotus International Pte Ltd in February 2023.
• Acquired the intellectual property and patents for its lead drug candidate from Spectrum Pharmaceuticals, Inc. in September 2018.

A Targeted Operational Model

Unicycive operates as a lean biotechnology firm that acquires drug candidates rather than discovering them in-house. This strategy allows its small team of 22 employees to focus on late-stage regulatory approvals and commercial planning.

Monitoring the Financial Path

• Net loss reached $12.8 million in Q1 2026, which worsened from a profit of $570,000 in Q1 2025.
• Operating losses deepened to $8.4 million for the quarter ended March 31, 2026, a 5.6% decline from the prior year.
• Cash and cash equivalents grew to $37.4 million by March 31, 2026, up from $29.2 million at the end of 2025.
• The company raised $19.6 million in net proceeds through stock sales managed by Guggenheim Securities, LLC during the first quarter of 2026.

Bottom Line

Unicycive has transitioned from a private start-up to a public biotechnology firm focused on advancing two specific kidney therapies. Its business model relies on clinical partnerships and equity financing to reach potential drug commercialization.